Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 149-154

  Heng, D Y C ^a   Choueiri, T K ^b   Rini, B I ^c   Lee, J ^d   Yuasa, T ^e   Pal, S K ^f   Srinivas, S ^g   Bjarnason, G A ^h   Knox, J J ⁱ   MacKenzie, M ^j   Vaishampayan, U N ^k   Tan, M H ^l   Rha, S Y ^m   Donskov, F ⁿ   Agarwal, N ^o   Kollmannsberger, C ^p   North, S ^q   Wood, L A ^r  

^a TOM BAKER CANCER CENTRE   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d University of Ulsan College of Medicine   (South Korea)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j LONDON HEALTH SCIENCES CENTRE   (Canada)

^k WAYNE STATE UNIVERSITY   (United States)

^l DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^m Yonsei University College of Medicine   (South Korea)

ⁿ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^o UNIVERSITY OF UTAH   (United States)

^p BRITISH COLUMBIA CANCER AGENCY   (Canada)

^q UNIVERSITY OF ALBERTA   (Canada)

^r QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

more..

Author keywords

Clinical trials; Ineligible; Metastatic renal cell cancer; Outcomes

Indexed keywords

AXITINIB; BEVACIZUMAB; CALCIUM; CREATININE; HEMOGLOBIN; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CRITERION VARIABLE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT INDICATION; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

CLINICAL TRIALS; INELIGIBLE; METASTATIC RENAL CELL CANCER; OUTCOMES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ELIGIBILITY DETERMINATION; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84897116337     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt492     Document Type: Article

References (15)

1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007; 356: 125-134.
3. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428.
4. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150.
5. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
6. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
7. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011; 378: 1931-1939.
8. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
10. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor targeted agents: results from a large multicenter study. J Clin Oncol 2009; 27: 5794-5799.
11. Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International metastatic renal cell carcinoma database consortium prognostic model: a population based study. Lancet Oncol 2013; 14: 141-148.
12. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
13. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded access trial. Lancet Oncol 2009; 10: 757-763.
14. Mol L, Koopman M, Van Gils CWM et al. Comparison of treatment outocome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in the Netherlands. Acta Oncol 2013; 52: 950-951.
15. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N et al. Clinical trial enrollment, patient characterisitics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009; 115: 4679-4687.